StoxGland Pharma vs Glaxosmithkline Pharmaceuticals: share price & financials comparison
NSE: GLAND vs GLAXO · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Gland Pharma vs Glaxosmithkline Pharmaceuticals at a glance
Gland Pharma (GLAND) has a market capitalisation of ₹55,016 Cr, against ₹45,277 Cr for Glaxosmithkline Pharmaceuticals (GLAXO). Over the past year Gland Pharma has returned +74.4%, compared with +0.5% for Glaxosmithkline Pharmaceuticals. On valuation, Gland Pharma trades at a lower P/E of 44.5 versus 87.9. Glaxosmithkline Pharmaceuticals earns a higher return on equity (27.4% vs 11.6%). Gland Pharma comes out ahead on valuation, growth, momentum and technicals. Glaxosmithkline Pharmaceuticals comes out ahead on size and profitability. Across the scored metrics below, Gland Pharma leads on 10 and Glaxosmithkline Pharmaceuticals on 5. On StoxGud's 10-point checklist, Gland Pharma scores 8/10 and Glaxosmithkline Pharmaceuticals scores 7/10.
| Metric | Gland Pharma | Glaxosmithkline Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹55,016 Cr | ₹45,277 Cr |
| Revenue (latest FY) | ₹6,431 Cr | ₹3,822 Cr |
| Net profit (latest FY) | ₹1,027 Cr | ₹1,036 Cr |
| Valuation | ||
| P/E | 44.5 | 87.9 |
| P/B | 5.15 | 24.07 |
| Dividend yield | 0.54% | 1.58% |
| Profitability | ||
| Return on equity | 11.6% | 27.4% |
| Net profit margin | 17.5% | 12.4% |
| Operating margin | 27.2% | 34.1% |
| Growth | ||
| Revenue growth (YoY) | +23.3% | +20.8% |
| Net profit growth (YoY) | +58.3% | — |
| Revenue CAGR (multi-year) | +13.2% | +2.9% |
| Financial health | ||
| Debt to equity | 0.02 | 0.00 |
| Momentum | ||
| 1-month return | +7.9% | +5.4% |
| 1-year return | +74.4% | +0.5% |
| 3-year CAGR | +27.0% | +22.0% |
| 5-year CAGR | -1.7% | +10.1% |
| 10-year CAGR | — | +7.2% |
| Distance from 52W high | +0.0% | -14.0% |
| Technicals | ||
| RSI (14) | 88 | 72 |
| Price vs 200-day avg | +42.4% | +5.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Gland Pharma | Glaxosmithkline Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Gland Pharma or Glaxosmithkline Pharmaceuticals?
Gland Pharma has a market cap of ₹55,016 Cr and Glaxosmithkline Pharmaceuticals has a market cap of ₹45,277 Cr as of 13 Nov 2026.
Which has a lower P/E, Gland Pharma or Glaxosmithkline Pharmaceuticals?
Gland Pharma has the lower P/E: Gland Pharma trades at 44.5 and Glaxosmithkline Pharmaceuticals at 87.9.
Which gave better returns in the last year, Gland Pharma or Glaxosmithkline Pharmaceuticals?
Gland Pharma did better: Gland Pharma returned +74.4% and Glaxosmithkline Pharmaceuticals returned +0.5% over one year.
What is the difference between Gland Pharma and Glaxosmithkline Pharmaceuticals?
Both are NSE-listed companies in Healthcare. Gland Pharma is about 1.2 times the size of Glaxosmithkline Pharmaceuticals by market cap. In the latest financial year Gland Pharma reported revenue of ₹6,431 Cr and Glaxosmithkline Pharmaceuticals ₹3,822 Cr. Operating margin is 27.2% for Gland Pharma and 34.1% for Glaxosmithkline Pharmaceuticals. Debt to equity is 0.02 for Gland Pharma and 0.00 for Glaxosmithkline Pharmaceuticals.
Which is better, Gland Pharma or Glaxosmithkline Pharmaceuticals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Gland Pharma leads on 10 and Glaxosmithkline Pharmaceuticals on 5. Gland Pharma is ahead on valuation, growth, momentum and technicals. Glaxosmithkline Pharmaceuticals is ahead on size and profitability. On StoxGud's rules-based checklist Gland Pharma scores 8/10 and Glaxosmithkline Pharmaceuticals scores 7/10. This is information, not advice: consult a SEBI-registered adviser before investing.